ProCE Banner Activity

New Strategies and Therapies for Managing Advanced Gastric Cancer

Clinical Thought

The treatment landscape for advanced gastric cancer is rapidly evolving and expanding. This expert commentary offers an overview of current recommended biomarker testing and corresponding treatment strategies as well as insights on adverse event management to provide optimal outcomes for patients with advanced gastric cancer.

Released: March 09, 2022

Expiration: March 08, 2023

No longer available for credit.

Share

Faculty

David H. Ilson

David H. Ilson, MD, PhD

Professor
Department of Medicine
Weill Cornell Medical College
Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Acknowledgement

This activity is supported by educational grants from Bristol-Myers Squibb and Merck & Co, Inc.

Provided by

ProCE Banner

Supporters

Bristol Myers Squibb

Merck & Co., Inc.

Target Audience

Oncology NPs, PAs, and nurses

Disclosure

Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.

None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.

Format

Clinical Thought

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Additional Information

Program Medium

This program has been made available online.